Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X:
“A guideline chatbot matched a prostate tumor board on 74.3% of cases. It missed local trials and frailty.
156 Málaga tumor board cases went through the EAU Guidelines Bot prospectively, board blinded.
Complete agreement 74.3%, clinically acceptable 89.7%
Of 39 discordant cases, 8 didn’t account for local trials or protocols and 6 missed frailty or comorbidity․
In metastatic disease, genetic testing was left out in 4 of 8 discordant cases․
A next version could check guideline NGS and germline testing in every case and always suggest a local trial when one is open.
Doctors aren’t replaced. Human in the loop takes this from close to concordant.
Tumor board is about multidisciplinary care. Could we run an AI council with a voice for each specialty, urology, Radiation Oncology, radiology, pathology and Medical Oncology?
Title: Real-World Concordance of the European Association of Urology Guidelines Bot With Multidisciplinary Decision-Making in Prostate Cancer: A Prospective Study
Authors: Alfonso Romero Crespo, Javier Fernandez Siles, Rodrigo España Navarro
Other articles about AI and Prostate Cancer on OncoDaily.